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Introduction
Ulcerative colitis [UC] is a chronic inflammatory condition of the bowel characterized by a relapsing and remitting course. 1 This disease [IBD] causes a continuous mucosal inflammation of the colon that can affect the rectum and a variable extension of the colon. 1 The characteristic lesions found in the mucosa are intense basal plasmacytosis-defined as presence of plasma cells around or below the crypts-an increase in the diffuse transmucosal lamina propria cells, and a widespread architectural distortion of the mucosa or crypts. 2 Mucosal healing [MH] , routinely assessed by endoscopy, is considered a prognostic marker, as it has been described as able to predict disease outcomes such as steroid need, hospitalization, and colectomy. [3] [4] [5] Therefore, MH has emerged as an important clinical factor in disease progression, both for Crohn's disease and UC patients. 3, 4, 6, 7 However, from an histological point of view, recovery is often incomplete, and microscopic evidence of inflammation persists in 16-100% of the patients with endoscopically quiescent colitis. 5, 8 In fact, histologic changes tend to lag behind clinical response and/or remission after starting UC treatment. This quiescent inflammation puts patients at risk of further disease relapses or of developing disease complications. 5, 8 On the other hand, histological remission was shown to decrease colorectal cancer risk in UC. 7, 9 Many histological indices have been described since the 1950s for assessing the microscopic activity in UC patients; however, until recently none of them had been fully validated. Geboes et al. developed a reproducible six-graded classification system that accurately discriminates UC patients according to structural changes and chronic and acute inflammatory activity. Currently, the Geboes index [2000] is considered to be the best classification system for histological assessment of UC, having a kappa coefficient for interobserver variation of 0.59-0.70. 10 Given that histological remission is considered to be a different target than the endoscopic MH in UC patients, the histological assessment of disease activity has been increasingly used by physicians. 11 Faecal calprotectin [FC] is considered to be an excellent marker of intestinal inflammation, as it reflects the migration of neutrophils through the inflamed bowel wall to the mucosa. 2 Multiple studies have revealed that FC is a precise diagnostic tool-distinguishing IBD from non-IBD patients-and FC concentrations seem to correlate well with the degree of histological and endoscopic inflammation. [12] [13] [14] [15] Although not studied as well as FC, neutrophil gelatinase B-associated lipocalin [NGAL] has also been suggested as a potential surrogate marker for IBD diagnosis and monitoring. In fact, a few recent studies have demonstrated that NGAL is elevated in the serum of IBD patients (when compared with healthy controls or irritable bowel syndrome [IBS] patients) and have reported different cut-off values for predicting histological remission and MH. [16] [17] [18] [19] Moreover, other studies have demonstrated that faecal NGAL levels are a reliable marker of UC activity. 20 The primary aim of the present study was the evaluation of the accuracy of FC for assessing both MH and histological remission in UC patients without clinical symptoms. Its primary endpoints were:
[i] to establish the prevalence of histologic inflammation and endoscopic activity in patients with clinically asymptomatic UC; and [ii] to evaluate the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of FC for assessing histological and/or endoscopic activity. Additionally, NGAL was quantified in a subset of patients and evaluated for the same purpose as FC.
Materials and Methods

Patients and study design
This was a nationwide and multicentre study: the patients included had a definitive diagnosis of UC, according to ECCO guidelines, 2 and were being followed in nine Portuguese IBD specialized centres. The inclusion criteria were: [i] UC patients older than 18 years old; and [ii] absence of symptoms according to the Montreal classification and Mayo partial score of <2. The exclusion criteria were the use of topic therapies and the presence of clinical symptoms.
All the patients enrolled in this study did so voluntarily and signed a written informed consent. The study was approved by the ethics committees of all hospitals involved and by the Portuguese Data Protection Authority [Comissão Nacional de Protecção de Dados]. The national coordinator of the Portuguese IBD group [GEDII] monitored the study.
All patients were subjected to blood analysis and collected faeces for the evaluation of FC and NGAL. A sigmoidoscopy was performed within 24 h of sample collection and without bowel preparation. During this examination sigmoid and rectum biopsies were taken. Endoscopic activity was evaluated by the Ulcerative Colitis Endoscopic Index of Severity [UCEIS] 21 and by the Mayo endoscopic subscore. 22 Patients were considered in remission whenever UCEIS was equal or below 1, whereas MH was defined as a Mayo endoscopic subscore equal to 0. 23 Finally, 19 patients who had a FC level above 250 μg/g and a normal endoscopic exam were subjected to a complete colonoscopy later on, after signing a new informed consent.
Histological assessment
The rectum and sigmoid biopsies [two of each] taken during the sigmoidoscopy were subject to central reading by three independent pathologists blinded regarding patients' disease status and endoscopic results. Disagreements between the pathologists were resolved by a review using a multiheaded microscope and including a fourth pathologist [Karel Geboes] in order to reach a final score. The histological assessment was performed using the Geboes index. 10 In this study, histological remission was defined as a Geboes index inferior to 3.1. Moreover, the degree of basal plasmacytosis was evaluated and classified according to the following scale: 0, absent; 1, focal; 2, diffuse. 24 
Faecal calprotectin and neutrophil gelatinase B-associated lipocalin
A single stool sample was collected from each patient and divided into smaller subsamples, on which FC and NGAL were quantified following the specific protocols described below. FC was extracted and quantified from the stool samples of 364 and 371 patients, using the QB and the EliA kits respectively [ 
Results
Study population
This cohort enrolled 371 asymptomatic UC patients who were consecutively enrolled in this study, and whose demographic and clinical characteristics are depicted in Table 1 . The female proportion of the population was 53%, while the patients' median [IQR] age was 47 years; the median [IQR] period during which the patients had been followed-up at medical care centres was 7 [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] years. Regarding UC localization, 57% had left-sided colitis and 43% had extensive colitis. A total of 366 patients were medicated: 91% were on oral mesalazine [5-ASA], 1% was on steroids, 30% were on azathioprine [AZT], and 10% were on anti-tumour necrosis factor [TNF] therapy. Moreover, 77 patients were dependent on steroids, 15 were steroid-resistant, and 21 were intolerant to AZT.
UC overall assessment: histological analysis, endoscopic activity and biomarker levels
The overall assessment of the UC activity in the patients included in this study is shown in Table 2 . Most of the patients were in remission according to the endoscopic examination: 91% according to UCEIS and 72% according to Mayo endoscopic subscore. These two approaches to the endoscopic results had an overall high correlation . Concerning FC levels, 47-69% of the studied patients were below the pre-established cutoff of 100 μg/g, depending on whether the quantification method was the QB or EliA, respectively. Moreover, the median [IQR] values of faecal NGAL were 9.00 μg/g [5. 30-18.10] .
The detailed histological assessment according to the Geboes index is shown in Table 3 . Despite being clinically asymptomatic, 20% of the patients presented with crypt involvement, 11.6% presented with crypt destruction, and 11% presented with some degree of erosion and ulceration. Figure 1 illustrates the occurrence of histological inflammation stratified according to the Mayo endoscopic subscore, the UCEIS, and the basal plasmacytosis grade. As expected, the relative frequency of patients with histological inflammation increased with the severity of the other outcomes. Nevertheless, it should be noticed that there was a considerable fraction of patients among those whom presented with no endoscopic lesions [10%], an UCEIS below 2 [15%] or no basal plasmacytosis [10%] , that still had a Geboes index of above 3.1 [ Figure 1 ]. The agreement rate between the Geboes index and other outcomes used in this study is shown in Table 4 : the highest accuracy rate [i.e. sum of true positives and true negatives] was found for the UCEIS [84%], whereas the accuracy rate concerning the Mayo endoscopic subscore was 79%.
Additionally, basal plasmacytosis was significantly associated with the presence of endoscopic lesions and histological activity [Supplementary Table 1 ]. In fact, 82% of patients without basal plasmacytosis had no endoscopic lesions, while 96% of them were in remission according to the UCEIS. Furthermore, 90% of patients without basal plasmacytosis had no histological inflammation, and the same percentage of patients with diffuse basal plasmacytosis had a Geboes index of ≥3.1.
Performance of FC and NGAL levels as UC biomarkers
The two different methods used to quantify the FC levels in patients' stools [ Irrespective of the method used, the FC levels had a consistent significant difference when compared between patients with or without histological and endoscopic activity [ Figure 2 and Supplementary  Tables 2 and 3 ]. In fact, and as it can be seen in Figure 2 , FC levels were significantly lower for patients without endoscopic lesions [Mayo endoscopic score of 0] when compared with those with lesions, as well as for patients with an UCEIS of <2. FC levels were also significantly lower for patients in histological remission when compared with those with a Geboes index ≥3. 1 The ability of FC levels to assess the presence of macroscopic and microscopic lesions in asymptomatic patients was evaluated by plotting a ROC curve for each case and computing the respective AUC [ Supplementary Figure 1 and Table 5 ]. The AUC values were quite similar between the QB and EliA methods, and all of them were significant; however, the AUC was smaller for the detection of endoscopic lesions when compared with the detection of histological inflammation and disease activity according to the UCEIS score. The sensitivity, specificity, positive predictive value [PPV], negative predictive value [NPV] and accuracy of the FC levels at different cutoffs for assessing histological and endoscopic activity are depicted in Table 5 . For the same cut-off values, the QB method of quantifying FC had a higher sensitivity, whereas the EliA method had a higher specificity. The best accuracy ratios were obtained using the EliA method with a cut-off of 250 or 300 μg/g: 77%, 70%, and 80% for the detection of a Geboes index ≥3.1, Mayo endoscopic subscore ≥1, and UCEIS ≥2, respectively. Even though the PPVs were low in this situation [16-46%] , the NPVs were considerably high and ranged from 74% for the detection of macroscopic lesions to 92% for the detection of an UCEIS above or equal to 2. Moreover, a ROC curve was built for the FC values considering the presence of either histological or endoscopic remission [according to UCEIS or Mayo endoscopic score], and the AUCs are indicated in Supplementary Table 4 , as well as the accuracy and related statistics of each cut-off. In this scenario, both the FC NPV and accuracy decrease slightly, although the PPV is a bit higher, especially when considering the detection of disease activity concerning UCEIS. The AUC tends to be lower than that for the detection of each outcome individually, with the exception of the detection of endoscopic lesions.
The presence of NGAL was inspected and quantified in a subset of 260 patients. At this point, it is important to highlight that this subset was similar to the left-out patients regarding the most important disease characteristics and outcomes, and so the inclusion of all patients would likely yield similar results [results not shown]. Upon stratifying NGAL concentrations according to the various analysed outcomes, the results have shown that NGAL levels were significantly lower for patients with no endoscopic lesions, with an UCEIS <2, or in histological remission, when compared with their counterparts [ Figure 3 and Supplementary Table 4 ].
The ability of NGAL to assess macroscopic and microscopic lesions was evaluated by plotting a ROC for each case and computing the AUCs [Supplementary Figure 1 and Table 6 ]. All AUCs were statistically significant and ranged from 0.635 to 0.713. The analyses of the NGAL cut-offs for each case are depicted in Table 6 : the highest accuracy ratio was obtained for a cut-off of 12 μg/g. For the detection of a Mayo endoscopic subscore ≥1, NGAL levels above 12 μg/g had an accuracy of 64% and a NPV of 77%; regarding the detection of UCEIS ≥2, the same cut-off had an accuracy ratio of 64% and an NPV of 93%; finally, for the detection of a Geboes index ≥3.1, the ratio was 62% and the NPV was 83%. As with the FC, the PPVs regarding NGAL cut-offs were considerably lower [between 15% and 43%]. Moreover, a ROC curve was built to evaluate the performance of NGAL in the detection of either histological or endoscopic remission [according to UCEIS or Mayo endoscopic score]. AUC, accuracy, and related statistics are indicated in Supplementary Table 4 : when compared against their counterparts in the specific analysis of each outcome, both accuracy and PPV tend to be higher, whereas NPV tends to be lower. The AUC is generally lower than that for the detection of each outcome individually.
The AUCs of the ROC curves using the CRP for the detection of the outcomes mentioned above were also computed [ Supplementary  Figure 1] . However, the AUC was in all cases non-significant and below that of the faecal markers.
Cut-off values of 150 μg/g for the EliA method, 250 μg/g for the QB method and 12 μg/g for NGAL were chosen as the ones presenting a better balance between sensitivity, specificity, PPV and NPV. The overall accuracy and kappa index for FC and NGAL using these Combining the two studied biomarkers-FC and NGALseems like a rational approach to increase their detection potential. However, such combination did not seem to yield better results than the utilization of each marker alone [Supplementary Table 6 ]. In fact, although there is an increase in the accuracy [mostly due to an increase in specificity], this difference does not seem to hold any significance on the daily clinical practice, as NPVs remained fairly unchanged.
Sigmoidoscopy vs. colonoscopy
To further explore the relation between FC levels and macroscopic lesions, patients who had FC levels above 250 μg/g and a normal sigmoidoscopy were invited to do a complete colonoscopy a few months after [data not shown]. Nineteen patients accepted the invitation to do so. Interestingly, in 16 of those patients macroscopic lesions were detected in or above the sigmoid colon, and in 12 of those 16 there was also an increase in the Geboes index.
The choice of a sigmoidoscopy as the patient's initial endoscopic examination instead of a colonoscopy had the rational of avoiding mechanical bowel preparation [known to cause structural changes and inflammation, and therefore prone to causing some bias in the results]. 25, 26 Nonetheless, a sigmoidoscopy is unable to detect lesions above the lower third of the colon, and therefore one could raise the question of whether a more complete examination would change the results. In order to address that issue, patients were stratified according to their disease location-left-side or extensive colitis. These groups were individually analysed regarding FC and NGAL cut-offs [Supplementary Tables 7 and 8] , and the results showed that the 95% CI for sensitivity, specificity, PPV, NPV, and accuracy were, in the vast majority of cases, overlapping between them.
Discussion
The gold standard for monitoring disease activity in UC patients still includes a colonoscopy, usually followed by the histological analysis of sampled biopsies. However, colonoscopies are invasive and time-consuming procedures, are relatively expensive, and cause discomfort to the patients. For these reasons, the optimization and validation of biomarkers that can accurately diagnose or monitor disease progression in UC [and other IBD] patients is highly desirable. Among the many biomarkers that have been explored in this context, FC-a calcium-binding protein that composes up to 60% of the neutrophils' cytosol-stands out as a particularly promising one. The presence of calprotectin in faeces reflects the leakage of neutrophils into the bowel lumen, usually caused by an inflammatory process that alters the mucosal architecture. Hence, FC is expected to mirror the integrity of the bowel mucosa.
Many studies have been made in the last two decades to measure the value of FC in diagnosing and monitoring disease activity in IBD patients. [27] [28] [29] However, the vast majority of these studies have focused on the ability of FC to discriminate IBD patients from healthy volunteers or patients with irritable bowel syndrome [IBS] , or on predicting disease activity in IBD patients. This study has the particularity of focusing on asymptomatic UC patients [N = 371], and reporting on the value of FC for assessing endoscopic and histological activity in patients that have a definitive diagnosis but no clinical activity of the disease. Additionally, the faecal NGAL levels were also accounted for in this context [in 260 patients of this cohort].
As expected-given the absence of symptoms-most patients were in MH according to the Mayo endoscopic subscore [72%], in remission according to the UCEIS [91%], or had no microscopic signs of inflammation [Geboes <3.1] [79%]. However, the agreement between these different evaluations was only moderate [79-84%]. In fact, there were a number of patients with a Geboes index above 3.1 who were considered to be in remission according to the Mayo endoscopic subscore and the UCEIS, and who had no basal plasmacytosis. Additionally, 15% of the patients with diffuse basal plasmacytosis were considered to be in MH [Mayo endoscopic subscore = 0], whereas 50% had a UCEIS <2. These results support the previously published notion that endoscopic findings fail to indicate the presence of microscopic activity and basal plasmacytosis, particularly in mild UC cases. 24, 30 Histological remission is a clinically relevant end-point that must be taken into consideration, as histological inflammation may be a better predictor of clinical relapses than endoscopic lesions in UC. 5 Moreover, and in the particular case of patients in clinical remission, the histology grade has the strongest association with the risk of clinical relapse. 31 The current literature concerning the utility of FC as an IBD biomarker agrees on its potential, but strongly disagrees on the cut-off values proposed-in fact, one can easily find variable FC cutoffs within the same context and for the same purpose. 28, 29 This is likely to be in part due to the variety of commercial kits currently available for quantifying FC, which are based on a similar method [ELISA] but may differ in specific details [e.g. monoclonal vs. polyclonal antibodies]. To tackle this issue, two different FC quantification kits were used in this study: the QB and the EliA. And whereas the results had a high intraclass correlation index, they were rather distant in terms of average and median values. Furthermore, the stratification of patients according to the pre-established cut-off of 100 μg/g yielded different-sized groups for each of the two methods. Notwithstanding, and despite the absolute levels quantified, QB and EliA had a similar variation for the different grades of histological activity and endoscopic lesions in UC asymptomatic patients. So, different cut-offs have to be optimized and validated for each kit and within each context.
Overall, the ROC analysis of the FC levels revealed that FC is a good predictor of macroscopic and microscopic activity in asymptomatic UC patients. As cut-off values, and considering the best balance between specificity, sensitivity, PPV, NPV, and accuracy, one should consider 150 μg/g for the EliA method, and 250 μg/g for the QB method. Given the low prevalence of inflammatory activity in the asymptomatic patients, these cut-off values present considerably high NPVs. So, negative test results can exclude the presence of endoscopic activity and microscopic inflammation with an appreciable degree of certainty, which can spare the patient from an unnecessary colonoscopy. On the other hand, the PPVs tend to be low and never reach 50%. For that reason, a positive result [i.e. a test result above the proposed thresholds] must be interpreted with caution, and should not be used as the sole basis to justify a complete colonoscopy. Such an invasive procedure should only be carried out Interestingly, Guardiola et al. 32 have recently proposed that an FC concentration of lower than 155 μg/g can indicate the absence of acute inflammatory infiltrate with a NPV of 89% in UC patients considered to be in clinical and endoscopic remission. Our study validates and expands this previous report, using a much larger cohort [371 vs. 59], a validated histological index, and including the UCEIS and the basal plasmacytosis assessment.
Additionally, two other studies have reported the potential of FC to predict MH and/or disease flares in patients with quiescent UC. 33, 34 However, these studies have not included the histological assessment of the patients. Given the importance of the histological remission as a primary end-point in UC, particularly in the case of patients considered to be in clinical remission, 5, 31 we believe that our study offers a more inclusive approach to studying the usefulness of FC in assessing asymptomatic patients. Moreover, in one of those studies, 33 the FC cut-off proposed [50 to 13.9 μg/g] was much lower then the ones we report here. Whereas the use of topical medication in 15% of the patients included in that study may have contributed to the different values obtained, the use of a different commercial kit to quantify the FC is likely the reason for the generally lower FC levels reported, consequently resulting in a lower cut-off. This reinforces the idea postulated earlier that each kit requires a specific optimization and validation of the cut-off [s] .
As a secondary outcome of this study, the potential of faecal NGAL for assesings MH and histological remission was evaluated in 260 patients. The AUCs of the NGAL levels computed for the Geboes index, the Mayo endoscopic subscore, and the UCEIS were significant and ranged from 0.653 to 0.713. The accuracy ratios were lower than those obtained for FC. Still, a cut-off of 12 μg/g can be useful in the assessment of disease activity. Whereas the number of false positives was rather high, the number of false negatives was very low, and therefore a test result below 12 μg/g can exclude the presence of histological activity with a probability of 83%, the presence of endoscopic lesions with a probability of 77%, and an UCEIS equal to or above 2 with a probability of 93%.
Combining the two biomarkers did not increase the accuracy of the test. Such a result was not unexpected: in fact, as the source of calprotectin and NGAL is the same-the neutrophils-both biomarkers are expected to reflect the leakage of these cells into the lumen, and therefore they should be redundant. Moreover, the AUCs for the CRP assessment of endoscopic and histological outcomes were non-significant and below those of FC and NGAL, suggesting that faecal markers are likely a better approach for detecting active disease at least in asymptomatic UC patients. Nevertheless, the combination of FC and/or NGAL with biomarkers of a different nature merits further attention in the future.
The utilization of a sigmoidoscopy as the initial patient's examination could be considered a limitation, as lesions above the lower third of the colon could not be detected. However, a sigmoidoscopy avoids bowel preparation, which could affect the colon inflammation. Moreover, the 95% CI intervals for sensitivity, specificity, PPV, NPV, and accuracy regarding FC and NGAL cut-offs are, in the vast majority of cases, overlapping for patients with left-side or extensive colitis. This demonstrates that the presence of lesions undetected in the sigmoidoscopy do not affect the overall results, and therefore the examination performed was adequate and sufficient for this study.
The main strengths of this study were the considerable large size of the cohort, the collection of stool samples for FC and NGAL analysis in a period of 24 h prior to the sigmoidoscopy, the use of two different assays for quantifying the FC, the use of a well-known and strong index for the histological assessment [Geboes index] , and the fact that the biopsies were analysed by independent pathologists blinded to the disease status. The more recent validated histological indices were indeed not yet published when this study was designed. 35, 36 As for limitations, one should account for the fact that FC quantification was based on a single sample-De Vos et al. have recently shown that two consecutive measurements of calprotectin are more specific than a single one for the prediction of relapses. Moreover, this was a cross-sectional study, and therefore the progression of the disease-along with that of the FC and NGAL levels-was not accounted for.
In conclusion, this study reports the presence of histological inflammation and even macroscopic lesions among asymptomatic UC patients, and points out that FC and faecal NGAL levels can be useful for dismissing the presence of histological and endoscopic activity, therefore reducing the number of unnecessary colonoscopies. FC and NGAL are, therefore, clinically relevant biomarkers, as they can aid the physician in the follow-up assessment of UC patients without clear symptoms. Their utility to predict the presence of lesions is, however, limited, and their utilization for this purpose must be complemented by the use of other markers. Moreover, further studies are needed to validate the proposed cut-off values, as well as to extend them with a follow-up approach, in order to determine whether these [or other] values could also be useful for the anticipation and prevention of flares.
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